Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lukas BiomedicalROCO:6814 +4.45%66 Quick Ratio is 0.50 as of Dec. 2025, which is 38% below its 10-year median of 0.80. GuruFocus rates ROCO:6814 with a GF Score™ of 66/100 and a GF Value™ of NT$21.77 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 1,411 Biotechnology companies, Lukas Biomedical ranks worse than 89.37% on this metric.
Lukas Biomedical has a quick ratio of 0.50. It indicates that the company cannot currently fully pay back its current liabilities.
The historical rank and industry rank for Lukas Biomedical's Quick Ratio or its related term are showing as below:
ROCO:6814'
s Quick Ratio Range Over the Past 10 Years
Min: 0.5 Med: 0.8 Max: 1.52
Current: 0.5
During the past 8 years, Lukas Biomedical's highest Quick Ratio was 1.52. The lowest was 0.50. And the median was 0.80.
ROCO:6814's Quick Ratio is ranked worse than 89.37% of 1411
companies
in the Biotechnology industry
Industry Median: 3.59
vs ROCO:6814: 0.50
Lukas Biomedical (ROCO:6814) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Lukas Biomedical Quick Ratio Related Terms
Lukas Biomedical Quick Ratio Historical Data
* Premium members only.
The historical data trend for Lukas Biomedical's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6814 vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, Lukas Biomedical's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lukas Biomedical Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lukas Biomedical's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Lukas Biomedical's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Lukas Biomedical's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lukas Biomedical (ROCO:6814) has a Quick Ratio of 0.50 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Lukas Biomedical and its competitors. This is 38% below median its historical median of 0.80. Over the past decade, Lukas Biomedical's Quick Ratio has ranged from 0.50 to 1.52. According to the industry distribution chart, Lukas Biomedical ranks #1261 out of 1411 companies in the Biotechnology industry, placing it in the top 89.4%.
Is Lukas Biomedical's Quick Ratio too high?
Lukas Biomedical's current Quick Ratio of 0.50 is 38% below median its 10-year median of 0.80. Over the past 10 years, this metric has ranged from a low of 0.50 to a high of 1.52. The Biotechnology industry median Quick Ratio is 3.59. Lukas Biomedical's value of 0.50 is 86.1% below this industry median. Based on the distribution chart, Lukas Biomedical ranks #1261 out of 1411 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lukas Biomedical has a GF Score™ of 66/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lukas Biomedical's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lukas Biomedical ranks #1261 out of 1411 companies for Quick Ratio. This places Lukas Biomedical in the lower half of its industry. The industry median Quick Ratio is 3.59. Lukas Biomedical's value of 0.50 is 86.1% below this benchmark. Historically, Lukas Biomedical's own Quick Ratio has ranged from 0.50 to 1.52 over the past decade. While the company's 10-year median is 0.80 vs. the industry median of 3.59, Lukas Biomedical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.59, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lukas Biomedical's current Quick Ratio of 0.50 is 86.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Lukas Biomedical and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lukas Biomedical's current Quick Ratio is 0.50, which is 38% below median its own 10-year median of 0.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lukas Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Lukas Biomedical (ROCO:6814) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$21.77, compared to a current price of NT$24.65 — trading 13.2% above its estimated fair value. The current Quick Ratio is 0.50, which is 38% below median its 10-year median of 0.80 and 86.1% below the Biotechnology industry median of 3.59. Lukas Biomedical's overall GF Score™ is 66/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Lukas Biomedical (ROCO:6814), the current Quick Ratio is 0.50 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lukas Biomedical (ROCO:6814) Overvalued in 2026?
Based on GuruFocus' analysis, Lukas Biomedical stock appears to be overvalued.
The current stock price of NT$24.65 is trading 13.2% above its estimated GF Value™ of NT$21.77.
GuruFocus considers Lukas Biomedical to be Modestly Overvalued.
Key valuation signals for ROCO:6814:
Quick Ratio: 0.50 (38% below median its 10-year median of 0.80)
GF Value™: NT$21.77 vs. price of NT$24.65 (13.2% above fair value)
Industry Position: 86.1% below the Biotechnology median (#1261 of 1411)
No single metric tells the full story. See the ROCO:6814 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lukas Biomedical Inc. is engaged in researching and developing immunotherapy for cancer treatment technologies. The company's main business activities include developing immunocellular therapy, leasing and selling medical equipment, and selling biotech beauty products.
66GF Score
Get the complete analysis for ROCO:6814
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6814 has been successfully added to your 
